MetaCap

Maravai LifeSciences (MRVI) vs Trevi Therapeutics (TRVI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Maravai LifeSciences (MRVI) has outperformed Trevi Therapeutics (TRVI) over the past year, gaining 86.1% versus a gain of 21.5%. Over five years, TRVI leads with a +1235.0% price change compared with -83.2% for MRVI. Trevi Therapeutics is the larger company by market cap ($1.90 billion vs $1.81 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MRVI+86.13%TRVI+21.47%
+148%+58%-33%
Nov 21, 20251 yearNov 20, 2026
MRVI-81.37%TRVI+1159.43%
+1789%+802%-185%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MRVI versus TRVI key metrics
MetricMRVITRVI
Share price$6.98$13.35
Market cap$1.81B$1.90B
1-day change-2.92%-2.70%
YTD return+114.77%+6.63%
1-year return+86.13%+21.47%
5-year return-83.18%+1235.00%
EPS (TTM)$-0.44$-0.40
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$185.74M—
Revenue growth (YoY)-28.34%—
Net income (latest FY)$-130.77M$-42.76M
Gross margin18.30%—
Operating margin-115.89%—
Net margin-70.41%—
52-week high$9.42$20.22
52-week low$2.80$9.82
Distance from 52-week high-25.90%-33.98%
Analyst consensusbuystrong_buy
Avg. price target upside+38.11%+111.09%
Average volume2.72M2.00M
Shares outstanding149.25M142.56M
Employees41034
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MRVI has outperformed TRVI by 64.7 percentage points over the past year.

About Maravai LifeSciences

MRVI stock →

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.

Health Care · Biotechnology: Pharmaceutical Preparations · 410 employees

About Trevi Therapeutics

TRVI stock →

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.

Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees

MRVI vs TRVI FAQ

Which is bigger, Maravai LifeSciences or Trevi Therapeutics?

Trevi Therapeutics (TRVI) is larger, with a market capitalization of $1.90B compared with $1.81B for Maravai LifeSciences (MRVI).

Which stock has performed better over the past year, MRVI or TRVI?

MRVI returned +86.13% over the past 12 months, compared with +21.47% for TRVI (price return, excluding dividends). Past performance does not predict future results.

Are Maravai LifeSciences and Trevi Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons